Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00263679 | Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine. | PHASE3 | COMPLETED | 321 | — | — | Nov 1, 2003 | Oct 1, 2004 | Sep 15, 2016 | 13 | Germany |
| Name | Type | Description |
|---|---|---|
| Prophylaxis: Diphtheria, tetanus and pertussis | BIOLOGICAL | - |
Inclusion Criteria: \- Subjects previously enrolled and vaccinated in GSK Biologicals' studies APV-118 and APV-120 and who were 9 through 13 years of age Exclusion Criteria: * Use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the a...